Why Kazakhstan continues to use hydroxychloroquine to treat COVID-19 patients

NUR-SULTAN. KAZINFORM – Kazakhstan's leading infectious disease physician Dinagul Baesheva spoke about why the country hasn’t followed the footsteps of the WHO and the U.S. and continues to treat COVID-19 patients with hydroxychloroquine, Kazinform correspondent reports.

Related news

Kazakhstan added over 1,000 new cases of pneumonia in past day

More COVID-19 recoveries reported in Kazakhstan, total at 71,609 Kazakhstan reports 907 new COVID-19 cases for past day Defense Minister reports to President on Concept of Kazakh Armed Forces development

Speaking at an online briefing of the Central Communications Service, Baesheva pointed out that the disease (COVID-19) causes different pathogeneses.

According to her, hydroxychloroquine is used in patients depending on the severity of their condition and clinical laboratory specifics. She also mentioned that hydroxychloroquine had been extensively appropriated in some European countries and the U.S. According to her, no fatalities caused by hydroxychloroquine have been reported yet.

She went on to say that given the risks and benefits hydroxychloroquine is used in a COVID-19 patient for five days. She insisted good results had been observed after the treatment with hydroxychloroquine. That is why, in her words, it is included in the medical protocol.